Table 1.
Baseline characteristics of control and T2DM groups based on obesity
| Control | T2DM | |||
|---|---|---|---|---|
| Lean | Obese | Lean | Obese | |
| Female (%) | 6 (27.3%) | 13 (68.4%)* | 18 (24%) | 61 (87.1%)* |
| Age (year) | 50.4 ± 9.9 | 55.5 ± 12 | 54.9 ± 10.9 | 54.2 ± 10.9 |
| BMI (kg/m2) | 25 ± 2.7 | 29.1 ± 2.3* | 25.6 ± 3.3 | 29.8 ± 4.1* |
| WC (cm) | 88.7 ± 7.7 | 101.8 ± 6.8* | 88.4 ± 8.5 | 101 ± 8.4* |
| Weight (kg) | 67.3 ± 10.7 | 81.6 ± 9.9* | 69.5 ± 9.1 | 80 ± 12.3* |
| T2DM duration (years) | – | – | 6.3 ± 7.6 | 4.5 ± 4.9 |
| Metformin | – | – | 7 (50%) | 7 (50%) |
| Glibenclamide | – | – | 23 (53.5%) | 20 (46.5%) |
| Met + Glb | – | – | 37 (50%) | 37 (50%) |
| FBS (mg/dL) | 83.2 ± 6 | 89.1 ± 9.2* | 190.5 ± 85.7# | 189.6 ± 72.9# |
| Triglyceride (mg/dL) | 110.5 ± 54.2 | 163.4 ± 61.3* | 175.8 ± 86.2# | 187.4 ± 88.8 |
| Cholesterol (mg/dL) | 186.1 ± 24.1 | 179.7 ± 40.7 | 197.6 ± 46.5 | 199.1 ± 43.4 |
| LDL-C (mg/dL) | 93.2 ± 13.7 | 92.3 ± 21.5 | 95.3 ± 38.8 | 92 ± 39 |
| HDL-C (mg/dL) | 48.3 ± 16.2* | 37.4 ± 8.7 | 43 ± 10.3 | 41.1 ± 9.6 |
| Creatinine (mg/dL) | 0.9 ± 0.1 | 1 ± 0.2 | 0.9 ± 0.2 | 1 ± 0.4 |
| HOMA-IR | 3 ± 1 | 5.9 ± 7.4 | 8.7 ± 8.5# | 7.4 ± 5.3 |
| hs-CRP (mg/L) | 1.6 ± 1.2 | 2.5 ± 1.9 | 9.5 ± 16.2# | 16.7 ± 26.4#* |
| Insulin (mIU/L) | 14.6 ± 4.7 | 26.4 ± 31.7 | 17.5 ± 13.4 | 16.4 ± 11.3# |
| HSP70 (ng/mL) | 0.3(0.1–2) | 0.5(0.1–2) | 0.6(0.3–1)# | 0.6(0.2–1) |
*Show a significant difference between obese and lean subjects in control and T2DM groups separately (p < 0.05)
#Shows a significant difference between T2DM patients and healthy subjects in lean and obese group separately
Central obesity is defined by WC > 102 cm or 88 cm for men and women, respectively. FBS: fasting blood sugar, LDL-C: low-density lipoprotein-cholesterol, HDL-C: high-density lipoprotein-cholesterol, HOMA-IR, homeostatic model assessment-insulin resistance, hs-CRP: high sensitivity C-reactive protein, HSP70: heat shock protein 70, T2DM: type 2 diabetes